Brokerages Set Moderna, Inc. (NASDAQ:MRNA) PT at $100.44

by · The Cerbat Gem

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has earned an average recommendation of “Hold” from the nineteen ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $100.44.

MRNA has been the subject of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, September 13th. The Goldman Sachs Group cut their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Evercore ISI reissued an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. TD Cowen cut their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Finally, Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th.

Get Our Latest Stock Report on MRNA

Moderna Trading Down 1.4 %

Shares of MRNA stock opened at $60.20 on Friday. The stock has a market cap of $23.07 billion, a P/E ratio of -3.84 and a beta of 1.66. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna has a fifty-two week low of $59.62 and a fifty-two week high of $170.47. The business has a fifty day simple moving average of $78.45 and a 200-day simple moving average of $108.00.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same period last year, the firm posted ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. On average, analysts forecast that Moderna will post -9.86 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,158 shares of company stock worth $9,259,012. 15.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Moderna by 22.6% during the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock worth $3,372,058,000 after buying an additional 6,248,623 shares during the last quarter. Wellington Management Group LLP lifted its stake in Moderna by 28.8% during the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after purchasing an additional 1,614,460 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after purchasing an additional 463,960 shares during the last quarter. Matrix Capital Management Company LP acquired a new position in Moderna in the fourth quarter worth $45,150,000. Finally, Nikko Asset Management Americas Inc. increased its stake in Moderna by 156.9% during the first quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock valued at $79,044,000 after purchasing an additional 453,004 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

(Get Free Report

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories